Disclosed is an
AMPK activating material used for improving and treating
metabolic syndrome, in which
AMPK (AMP-activated
protein kinase) is a main
enzyme for regulating an energy sensor and lipid / glucose
metabolism in the body. The activation of
AMPK inhibits the synthesis of fat and
cholesterol, and accelerates the reduction of body fat and blood glucose, thereby improving
obesity, diabetes, and hyperlipidaemia. The disclosed AMPK activating material contains, as active ingredients having an improving and treating effect on
metabolic syndrome, including
obesity, diabetes, and hyperlipidaemia, a novel compound 2α,3β,12β-trihydroxydammar-20(22)-E,24-
diene-3-O-[β-D-glucopyranosyl-(1→)-β-D-glucopyranoside], named Damulin A, and a novel compound 2α,3β,12β-trihydroxydammara-20,24-
diene-3-O-[β-D-glucopyranosyl-(1→)-β-D-glucopyranoside], named Damulin B. Herein, the contents of damulin A and damulin B (as active indicator ingredients for AMPK activation) can be increased by treating a
Gynostemma pentaphyllum extract with high temperature /
high pressure. Accordingly, the novel
Gynostemma pentaphyllum extract with a significantly increased AMPK activating capability can be used for improving or treating
metabolic syndrome, such as
obesity, diabetes, and hyperlipidaemia.